Efficacy and safety of levetiracetam 1000-3000Â mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study

Conclusion: Levetiracetam as add-on therapy at doses up to 3000 mg/day effectively reduced the frequency of partial-onset seizures in patients with refractory epilepsy and was well-tolerated in this study, bridging conditions of placebo-controlled clinical trials and clinical practice.